List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2056926/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. Journal of Infectious Diseases, 2023, 227, 488-497.	4.0	10
2	Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. Cancer Letters, 2022, 525, 22-32.	7.2	18
3	Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer. Preventive Medicine, 2022, 155, 106906.	3.4	10
4	Arsenic, tobacco use, and lung cancer: An occupational cohort with 27 follow-up years. Environmental Research, 2022, 206, 112611.	7.5	7
5	Quantitative evaluation of radon, tobacco use and lung cancer association in an occupational cohort with 27 follow-up years. Ecotoxicology and Environmental Safety, 2022, 232, 113233.	6.0	8
6	Temporal Trends and Projection of Cancer Attributable to Human Papillomavirus Infection in China, 2007–2030. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1130-1136.	2.5	9
7	Effect of Time Since Smoking Cessation on Lung Cancer Incidence: An Occupational Cohort With 27 Follow-Up Years. Frontiers in Oncology, 2022, 12, 817045.	2.8	5
8	Triage performance and predictive value of the human gene methylation panel among women positive on self ollected <scp>HPV</scp> test: Results from a prospective cohort study. International Journal of Cancer, 2022, 151, 878-887.	5.1	9
9	Low cost versus other screening tests to detect cervical cancer or precancer in developing countries. The Cochrane Library, 2021, 2021, .	2.8	1
10	Association Between Common Vaginal Infections and Cervical Non–Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women. Journal of Infectious Diseases, 2021, 223, 445-451.	4.0	5
11	A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China. Vaccine, 2021, 39, 35-44.	3.8	42
12	Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial. Human Vaccines and Immunotherapeutics, 2021, 17, 955-964.	3.3	5
13	Health economic evaluation of primary human papillomavirus screening in urban populations in China. Cancer Epidemiology, 2021, 70, 101861.	1.9	5
14	Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China. Cancer Prevention Research, 2021, 14, 363-372.	1.5	1
15	Efficacy of pointâ€ofâ€care thermal ablation among highâ€risk human papillomavirus positive women in China. International Journal of Cancer, 2021, 148, 1419-1427.	5.1	15
16	Inequalities in Cervical Cancer Screening Uptake Between Chinese Migrant Women and Local Women: A Cross-Sectional Study. Cancer Control, 2021, 28, 107327482098579.	1.8	3
17	Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Medicine, 2021, 19, 62.	5.5	18
18	Clinical evaluation of p16 <sup>INK4a</sup> immunocytology in cervical cancer screening: A populationâ€based crossâ€sectional study from rural China. Cancer Cytopathology, 2021, 129, 679-692.	2.4	2

#	Article	IF	CITATIONS
19	A nationwide post-marketing survey of knowledge, attitudes and recommendations towards human papillomavirus vaccines among healthcare providers in China. Preventive Medicine, 2021, 146, 106484.	3.4	9
20	Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China. Sexually Transmitted Infections, 2021, , sextrans-2021-055019.	1.9	3
21	Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China. Indian Journal of Gynecologic Oncology, 2021, 19, 51.	0.3	7
22	Has the human papillomavirus (HPV) immunization programme improved obstetric outcomes in spontaneous delivery? An ecological study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 262, 221-227.	1.1	0
23	Performance of cervical cancer screening and triage strategies among women living with HIV in China. Cancer Medicine, 2021, 10, 6078-6088.	2.8	5
24	Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study. The Lancet Regional Health - Western Pacific, 2021, 13, 100196.	2.9	5
25	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clinical Microbiology and Infection, 2021, 27, 1083-1095.	6.0	116
26	Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Intraepithelial Neoplasia in Chinese Women Living With HIV. Frontiers in Cellular and Infection Microbiology, 2021, 11, 703259.	3.9	11
27	The IARC Perspective on Cervical Cancer Screening. New England Journal of Medicine, 2021, 385, 1908-1918.	27.0	125
28	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. Journal of the National Cancer Institute, 2020, 112, 145-153.	6.3	99
29	Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. Cancer Medicine, 2020, 9, 374-384.	2.8	24
30	Comparison of the performance of paired urine and cervical samples for cervical cancer screening in screening population. Journal of Medical Virology, 2020, 92, 234-240.	5.0	8
31	Impact of HPV-16/18 ASO4-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial. BMC Infectious Diseases, 2020, 20, 846.	2.9	8
32	Development and validation of an artificial intelligence system for grading colposcopic impressions and guiding biopsies. BMC Medicine, 2020, 18, 406.	5.5	46
33	Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study. Clinical Epigenetics, 2020, 12, 62.	4.1	12
34	Comparative performance evaluation of different HPV tests and triaging strategies using selfâ€samples and feasibility assessment of thermal ablation in †colposcopy and treat' approach: A populationâ€based study in rural China. International Journal of Cancer, 2020, 147, 1275-1285.	5.1	26
35	Outcomes in women with biopsy-confirmed cervical intraepithelial neoplasia grade 1 or normal cervix and related cofactors: A 15-year population-based cohort study from China. Gynecologic Oncology, 2020, 156, 616-623.	1.4	9
36	Triage options to manage highâ€risk human papillomavirus <scp>â€</scp> positive women: A populationâ€based crossâ€sectional study from rural China. International Journal of Cancer, 2020, 147, 2053-2064.	5.1	17

#	Article	IF	CITATIONS
37	Comment on "Will HPV vaccination prevent cervical cancer― BMC Medicine, 2020, 18, 115.	5.5	2
38	Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 383-394.	2.2	4
39	Epidemiologic and Health Economic Evaluation of Cervical Cancer Screening in Rural China. Asian Pacific Journal of Cancer Prevention, 2020, 21, 1317-1325.	1.2	4
40	Eightâ€type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPVâ€positive women. International Journal of Cancer, 2019, 144, 34-42.	5.1	24
41	Training Future Leaders: Experience from China-ASEAN Cancer Control Training Program. Journal of Cancer Education, 2019, 34, 1067-1073.	1.3	1
42	Efficacy, immunogenicity and safety of the ASO4â€HPVâ€16/18 vaccine in Chinese women aged 18â€25Âyears: Endâ€ofâ€study results from a phase II/III, randomised, controlled trial. Cancer Medicine, 2019, 8, 6195-6211.	2.8	30
43	Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. Lancet Public Health, The, 2019, 4, e462-e472.	10.0	48
44	Cervical cancer prevention in China: a key to cancer control. Lancet, The, 2019, 393, 969-970.	13.7	93
45	Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China. Journal of Infectious Diseases, 2019, 219, 215-222.	4.0	10
46	Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 663-672.	2.2	12
47	Economic evaluation of cervical cancer screening strategies in urban China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 974-983.	2.2	8
48	Risk of high-risk human papillomavirus infection and cervical precancerous lesions with past or current trichomonas infection: a pooled analysis of 25,054 women in rural China. Journal of Clinical Virology, 2018, 99-100, 84-90.	3.1	18
49	Impact of International Collaborative Training Programs on Medical Students' Research Ability. Journal of Cancer Education, 2018, 33, 511-516.	1.3	5
50	Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan, China. Human Vaccines and Immunotherapeutics, 2018, 14, 404-411.	3.3	22
51	Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. Gynecologic Oncology, 2018, 148, 103-110.	1.4	22
52	Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China. Gynecologic Oncology, 2018, 151, 221-228.	1.4	11
53	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. Annals of Internal Medicine, 2018, 168, 20.	3.9	50
54	Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or. Clinical Laboratory, 2018, 64, 1363-1371.	0.5	4

#	Article	IF	CITATIONS
55	Pooled analysis on the necessity of random 4-quadrant cervical biopsies and endocervical curettage in women with positive screening but negative colposcopy. Medicine (United States), 2017, 96, e6689.	1.0	9
56	Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China. International Journal of Cancer, 2017, 141, 1110-1119.	5.1	18
57	Efficacy, immunogenicity, and safety of the HPVâ€16/18 ASO4â€adjuvanted vaccine in Chinese women aged 18–25Âyears: eventâ€triggered analysis of a randomized controlled trial. Cancer Medicine, 2017, 6, 12-25.	2.8	32
58	Risk Prediction of Cervical Cancer and Precancers by Type-Specific Human Papillomavirus: Evidence from a Population-Based Cohort Study in China. Cancer Prevention Research, 2017, 10, 745-751.	1.5	16
59	Management algorithms for cervical cancer screening and precancer treatment for resourceâ€limited settings. International Journal of Gynecology and Obstetrics, 2017, 138, 26-32.	2.3	45
60	Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China. International Journal of Cancer, 2017, 140, 544-554.	5.1	18
61	Prospective comparison of hybrid capture 2 and SPF10-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China. Journal of Gynecologic Oncology, 2017, 28, e66.	2.2	2
62	Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse. Journal of Gynecologic Oncology, 2017, 28, e47.	2.2	28
63	High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. Journal of Gynecologic Oncology, 2017, 28, e30.	2.2	36
64	Systematic Review and Meta-Analysis of Individual Patient Data to Assess the Sensitivity of Cervical Cytology for Diagnosis of Cervical Cancer in Low- and Middle-Income Countries. Journal of Global Oncology, 2017, 3, 524-538.	0.5	5
65	A retrospective analysis of the utility of endocervical curettage in screening population. Oncotarget, 2017, 8, 50141-50147.	1.8	8
66	Accuracy of triage strategies for human papillomavirus DNA-positive women in low-resource settings: A cross-sectional study in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 496-509.	2.2	15
67	Reply to Letter: Using novel risk stratification statistics to better understand the value of screening tests. International Journal of Cancer, 2016, 139, 1669-1669.	5.1	о
68	Elevated Expression of Human Papillomavirus-16/18 E6 Oncoprotein Associates with Persistence of Viral Infection: A 3-Year Prospective Study in China. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1167-1174.	2.5	11
69	Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. BMC Cancer, 2016, 16, 164.	2.6	23
70	Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China. BMC Cancer, 2016, 16, 848.	2.6	11
71	Risk assessment to guide cervical screening strategies in a large <scp>C</scp> hinese population. International Journal of Cancer, 2016, 138, 2639-2647.	5.1	16
72	Effectiveness of novel, lower cost molecular human papillomavirusâ€based tests for cervical cancer screening in rural china. International Journal of Cancer, 2016, 138, 1453-1461.	5.1	35

#	Article	IF	CITATIONS
73	How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China. Human Vaccines and Immunotherapeutics, 2016, 12, 39-46.	3.3	20
74	Estimation of Cancer Burden Attributable to Infection in Asia. Journal of Epidemiology, 2015, 25, 626-638.	2.4	18
75	The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer. Journal of Lower Genital Tract Disease, 2015, 19, 220-223.	1.9	14
76	Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening. BMC Cancer, 2015, 15, 848.	2.6	11
77	p16 Immunohistochemistry Interpretation by Nonpathologists as an Accurate Method for Diagnosing Cervical Precancer and Cancer. Journal of Lower Genital Tract Disease, 2015, 19, 207-211.	1.9	3
78	Random biopsy in colposcopy-negative quadrant is not effective in women with positive colposcopy in practice. Cancer Epidemiology, 2015, 39, 237-241.	1.9	9
79	Knowledge of human papillomavirus vaccination and related factors among parents of young adolescents: a nationwide survey in China. Annals of Epidemiology, 2015, 25, 231-235.	1.9	31
80	Distribution of cervical intraepithelial neoplasia on the cervix in Chinese women: pooled analysis of 19 population based screening studies. BMC Cancer, 2015, 15, 485.	2.6	4
81	Acceptability of human papillomavirus vaccine among parents of junior middle school students in Jinan, China. Vaccine, 2015, 33, 2570-2576.	3.8	33
82	Comprehensive cervical cancer prevention and control in the Asia Pacific region: the 6th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN). Journal of Gynecologic Oncology, 2014, 25, 170.	2.2	0
83	The low risk of precancer after a screening result of human papillomavirusâ€negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. Cancer Cytopathology, 2014, 122, 842-850.	2.4	25
84	Quality of life in women with cervical precursor lesions and cancer: a prospective, 6-month, hospital-based study in China. Chinese Journal of Cancer, 2014, 33, 339-45.	4.9	15
85	The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. Journal of Clinical Virology, 2014, 61, 553-557.	3.1	13
86	The Natural History of Cervical Cancer in Chinese Women: Results from an 11-Year Follow-Up Study in China Using a Multistate Model. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1298-1305.	2.5	14
87	A prospective study of age trends of high-risk human papillomavirus infection in rural China. BMC Infectious Diseases, 2014, 14, 96.	2.9	32
88	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncology, The, 2014, 15, 172-183.	10.7	508
89	p16 <sup>INK4A</sup> immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: A prospective study in China. International Journal of Cancer, 2014, 134, 1715-1724.	5.1	57
90	Lower cost strategies for triage of human papillomavirus DNAâ€positive women. International Journal of Cancer, 2014, 134, 2891-2901.	5.1	80

#	Article	IF	CITATIONS
91	Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial. International Journal of Cancer, 2014, 135, 2604-2611.	5.1	28
92	Efficacy, immunogenicity and safety of the HPVâ€16/18 ASO4â€adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial. International Journal of Cancer, 2014, 135, 2612-2622.	5.1	50
93	Liquid-based cytology and human papillomavirus testing: A pooled analysis using the data from 13 population-based cervical cancer screening studies from China. Gynecologic Oncology, 2014, 133, 172-179.	1.4	41
94	Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China. Journal of Clinical Microbiology, 2014, 52, 1954-1961.	3.9	14
95	Clinical Evaluation of Human Papillomavirus Detection by careHPV <sup>TM</sup> Test on Physician-Samples and Self-Samples using The Indicating FTA Elute® Card. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7085-7090.	1.2	16
96	Human Papillomavirus Vaccine Awareness, Acceptability, and Decision-Making Factors among Chinese College Students. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3239-3245.	1.2	31
97	Effect of an educational intervention on HPV knowledge and vaccine attitudes among urban employed women and female undergraduate students in China: a cross-sectional study. BMC Public Health, 2013, 13, 916.	2.9	66
98	Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China. Vaccine, 2013, 31, 3244-3249.	3.8	61
99	Six-Year Regression and Progression of Cervical Lesions of Different Human Papillomavirus Viral Loads in Varied Histological Diagnoses. International Journal of Gynecological Cancer, 2013, 23, 716-723.	2.5	29
100	An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China. Cancer Prevention Research, 2013, 6, 938-948.	1.5	88
101	Pooled analysis of the performance of liquidâ€based cytology in populationâ€based cervical cancer screening studies in China. Cancer Cytopathology, 2013, 121, 473-482.	2.4	40
102	Assessment of quality of life for the patients with cervical cancer at different clinical stages. Chinese Journal of Cancer, 2013, 32, 275-282.	4.9	25
103	Pooled Analysis of a Self-Sampling HPV DNA Test as a Cervical Cancer Primary Screening Method. Journal of the National Cancer Institute, 2012, 104, 178-188.	6.3	139
104	Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Services Research, 2012, 12, 123.	2.2	34
105	A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. Cancer Epidemiology, 2012, 36, 384-390.	1.9	95
106	Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 populationâ€based studies. International Journal of Cancer, 2012, 131, 2929-2938.	5.1	155
107	Analysis of the effectiveness of visual inspection with acetic acid/Lugol's iodine in one-time and annual follow-up screening in rural China. Archives of Gynecology and Obstetrics, 2012, 285, 1627-1632.	1.7	13
108	A Multi-center Survey of HPV Knowledge and Attitudes Toward HPV Vaccination among Women, Government Officials, and Medical Personnel in China. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2369-2378.	1.2	52

#	Article	IF	CITATIONS
109	Combined Screening of Cervical Cancer, Breast Cancer and Reproductive Tract Infections in Rural China. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3529-3533.	1.2	10
110	Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine, 2011, 29, 2487-2494.	3.8	69
111	Estimation of cancer cases and deaths attributable to infection in China. Cancer Causes and Control, 2011, 22, 1153-1161.	1.8	26
112	The association between dietary intake and cervical intraepithelial neoplasia grade 2 or higher among women in a high-risk rural area of china. Archives of Gynecology and Obstetrics, 2011, 284, 973-980.	1.7	9
113	Prevalence of HPV infection and cervical intraepithelial neoplasia and attitudes towards HPV vaccination among Chinese women aged 18–25 in Jiangsu Province. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2011, 23, 25-32	2.2	26
114	Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer, 2011, 11, 239.	2.6	51
115	Comparison of ThinPrep and SurePath liquidâ€based cytology and subsequent human papillomavirus DNA testing in China. Cancer Cytopathology, 2011, 119, 387-394.	2.4	41
116	Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded Programs. Journal of Infectious Diseases, 2011, 204, 335-337.	4.0	17
117	Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. International Journal of Cancer, 2010, 127, 646-656.	5.1	31
118	Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncology, The, 2010, 11, 1160-1171.	10.7	129
119	Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China. American Journal of Epidemiology, 2009, 170, 708-716.	3.4	29
120	A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncology, The, 2008, 9, 929-936.	10.7	416
121	Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China. International Journal of Cancer, 2006, 118, 442-448.	5.1	33
122	No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma: Result from a cross-sectional study in a high-risk region of China. International Journal of Cancer, 2006, 119, 1354-1359.	5.1	63